|
|
Post by sportsrancho on Aug 20, 2018 17:49:05 GMT -5
|
|
|
|
Post by babaoriley on Aug 20, 2018 19:20:21 GMT -5
Those people wouldn't do that, would they? I always figured those SA folk were 100% on the level, genuine, just like all posters on this board. I'm going to have to try to get my head around this.
|
|
|
|
SA
Aug 20, 2018 19:46:58 GMT -5
via mobile
Post by morgieporgie on Aug 20, 2018 19:46:58 GMT -5
Those people wouldn't do that, would they? I always figured those SA folk were 100% on the level, genuine, just like all posters on this board. I'm going to have to try to get my head around this. Paranoia - self destroyerrrrrrr.. |
|
|
|
Post by sportsrancho on Aug 20, 2018 19:49:34 GMT -5
Those people wouldn't do that, would they? I always figured those SA folk were 100% on the level, genuine, just like all posters on this board. I'm going to have to try to get my head around this. The bashers on Twitter now are going after the MNKD sales rep just like they were on here, as they are on stock twits. Of course that’s only one of their new favorite topics ...they are going literally insane, I’m thinking it speaks of a fear of a big move to the upside soon:-)) |
|
|
|
Post by joeypotsandpans on Aug 20, 2018 21:39:49 GMT -5
Those people wouldn't do that, would they? I always figured those SA folk were 100% on the level, genuine, just like all posters on this board. I'm going to have to try to get my head around this. The bashers on Twitter now are going after the MNKD sales rep just like they were on here, as they are on stock twits. Of course that’s only one of their new favorite topics ...they are going literally insane, I’m thinking it speaks of a fear of a big move to the upside soon:-)) I never did trust "fuzzy panda shorts" lol SA= Selectively Allow, selectively edit; quoting the author "fake news"  |
|
|
|
Post by boca1girl on Aug 21, 2018 7:52:17 GMT -5
Those people wouldn't do that, would they? I always figured those SA folk were 100% on the level, genuine, just like all posters on this board. I'm going to have to try to get my head around this. The bashers on Twitter now are going after the MNKD sales rep just like they were on here, as they are on stock twits. Of course that’s only one of their new favorite topics ...they are going literally insane, I’m thinking it speaks of a fear of a big move to the upside soon:-)) It feels like the heat has definitely been turned up. The bashers (shorts) have an easy out right now. They can cover at the current price and move on or go long, but I don’t see any evidence of that. I’m always hoping for that big move to the upside, hopefully you’re “thinking” is proven right very soon. |
|
|
|
Post by dh4mizzou on Aug 21, 2018 8:48:53 GMT -5
Boca,
Kind of makes one wonder who the shorts are and what their end game really is.
|
|
|
|
Post by peppy on Aug 24, 2018 6:11:39 GMT -5
At times my stupidity astounds me. For years I could not figure out why afrezza wasn't selling. It was/is that the health insurance industry has deals with Rapid Acting Insulin makers, and the insurance industry did not/ does not want to give up the lucrative kickbacks they have negotiated with the Big Pharma. ok, I get that now. Now my stupidity astounds me with Seeking Alpha. Heh, "catch and kill." their game? Spencer Osborne the David Pecker of Afrezza? Look at what has been caught and killed.   Game On. |
|
|
|
Post by sayhey24 on Aug 24, 2018 6:43:44 GMT -5
Peppy - afrezza is not selling because it is not properly represented in the standards of care. For example, if you want to reduce hypos the current standard says use RAAs with the T1s yet we know afrezza is better. If the standard said use afrezza before trying the RAA you would have insurance coverage and endo's prescribing.
|
|
|
|
Post by peppy on Aug 24, 2018 6:54:35 GMT -5
Peppy - afrezza is not selling because it is not properly represented in the standards of care. For example, if you want to reduce hypos the current standard says use RAAs with the T1s yet we know afrezza is better. If the standard said use afrezza before trying the RAA you would have insurance coverage and endo's prescribing. What are you talking about sayhey? I see meal time insulin. All they do is have to flunk. They are flunking. Additionally as you know type one's the standard of care IS meal time insulin. I will dig up the picture and post if I have to. ADDED: OK< I see what you are saying, Yes it says Injectable. We have to change that.  Insulin Therapy
Insulin is the mainstay of therapy for individuals with type 1 diabetes. Generally, the starting insulin dose is based on weight, with doses ranging from 0.4 to 1.0 units/kg/day of total insulin with higher amounts required during puberty. The American Diabetes Association/JDRF Type 1 Diabetes Sourcebook notes 0.5 units/kg/day as a typical starting dose in patients with type 1 diabetes who are metabolically stable, with higher weight-based dosing required immediately following presentation with ketoacidosis (1), and provides detailed information on intensification of therapy to meet individualized needs. The American Diabetes Association (ADA) position statement “Type 1 Diabetes Management Through the Life Span” additionally provides a thorough overview of type 1 diabetes treatment (2).  |
|
|
|
Post by mango on Aug 24, 2018 9:57:59 GMT -5
I just bookmarked this article. I’m curious if the author is familiar with SO. Eh, who am I kidding, of course he is! As peppy said, GAME ON. |
|
|
|
Post by mnholdem on Aug 24, 2018 12:29:36 GMT -5
Peppy - afrezza is not selling because it is not properly represented in the standards of care. For example, if you want to reduce hypos the current standard says use RAAs with the T1s yet we know afrezza is better. If the standard said use afrezza before trying the RAA you would have insurance coverage and endo's prescribing. What are you talking about sayhey? I see meal time insulin. All they do is have to flunk. They are flunking. Additionally as you know type one's the standard of care IS meal time insulin. I will dig up the picture and post if I have to. ADDED: OK< I see what you are saying, Yes it says Injectable. We have to change that. Insulin Therapy
Insulin is the mainstay of therapy for individuals with type 1 diabetes. Generally, the starting insulin dose is based on weight, with doses ranging from 0.4 to 1.0 units/kg/day of total insulin with higher amounts required during puberty. The American Diabetes Association/JDRF Type 1 Diabetes Sourcebook notes 0.5 units/kg/day as a typical starting dose in patients with type 1 diabetes who are metabolically stable, with higher weight-based dosing required immediately following presentation with ketoacidosis (1), and provides detailed information on intensification of therapy to meet individualized needs. The American Diabetes Association (ADA) position statement “Type 1 Diabetes Management Through the Life Span” additionally provides a thorough overview of type 1 diabetes treatment (2). This is where Dr Kendall needs to push for an updated Standards of Care. "Add rapid-acting insulin injections before meals" excludes inhaled insulin. Both should be listed. |
|
|
|
Post by peppy on Aug 24, 2018 12:36:49 GMT -5
my blood is boiling.
|
|
|
|
Post by mnholdem on Aug 24, 2018 12:40:41 GMT -5
Take an injection...  |
|
|
|
Post by mango on Aug 25, 2018 21:43:45 GMT -5
I personally would like to see publications continue to roll out & not stop at Dr. Anderson’s. I hope they will continue publishing papers, especially when a clinical trial is completed. I think the trial with One Drop is going to be a great success, can’t wait for that one to wrap up. And then we have the Levin trial set to be completed this year as well. I think the results from that one will be significant and meaningful. Hopefully there will be some great papers published by the MannKind SAB covering those studies. It will be monumental when the Peds trial is completed. Phase 3 will be here before we know it. IMO, Afrezza will become the Standard of Care for pediatrics after that. And, I believe it will become the first-line prandial insulin therapy for pediatrics, and subcutaneous prandial insulin formulations will be used as a second-line prandial insulin therapy option for peds—probably reserved for under rare/unique circumstances. TreT Phase 3 isn’t planned to start until 2019, and so I would like to see MannKind publish a paper on Technosphere-Treprostinil & PAH sometime soon, but I suppose that is on hold for specific reasons right now. I also can’t wait to see the inhalation device that will be used with TreT—Mike has not disclosed it publicly yet. I also think Dr. Anderson constructed a great paper. It is, IMO, the best one covering Afrezza that has been published in a long while. Hopefully it will not go unnoticed. On the event horizon—      |
|
